Engineered T Cells + Pembrolizumab for Pleural Cancer
Trial Summary
What is the purpose of this trial?
The purpose of this Phase I study is to test the safety of different doses of specially prepared immune cells (called "T cells") collected from blood. The Investigators want to find a safe dose of these modified T cells for patients who have malignant pleural disease. They want to find out what effects these T cells have on the patient and the cancer (MPD).Phase 2 part of the study, the investigators will test the dose in combination with another drug, pembrolizumab, to see what effects the study treatment has on malignant pleural mesothelioma.
Research Team
Roisin O'Cearbhaill, MD
Principal Investigator
Memorial Sloan Kettering Cancer Center
Eligibility Criteria
This trial is for adults with malignant pleural diseases like lung cancer or mesothelioma, who've had at least one prior treatment and show disease progression. They must have a functional pleural catheter, meet specific lab criteria (like certain blood cell counts), not be pregnant or breastfeeding, agree to use contraception, and can't have autoimmune diseases or need daily steroids.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
T Cell Preparation
Leukapheresis product is obtained and T cells are isolated, transduced, and expanded
Treatment
Participants receive CAR T cell infusion, with or without cyclophosphamide, followed by pembrolizumab administration
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Cyclophosphamide
- iCasp9M28z T cell infusions
- Pembrolizumab
Find a Clinic Near You
Who Is Running the Clinical Trial?
Memorial Sloan Kettering Cancer Center
Lead Sponsor
Bellicum Pharmaceuticals
Industry Sponsor
United States Department of Defense
Collaborator